Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

[1]  K. Ushijima,et al.  A randomized, phase III trial of paclitaxel plus carboplatin (TC) versus paclitaxel plus cisplatin (TP) in stage IVb, persistent or recurrent cervical cancer: Japan Clinical Oncology Group study (JCOG0505). , 2012 .

[2]  L. Muderspach,et al.  A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study. , 2001, Gynecologic oncology.

[3]  M. Plante,et al.  Simple Vaginal Trachelectomy in Early-Stage Low-Risk Cervical Cancer: A Pilot Study of 16 Cases and Review of the Literature , 2013, International Journal of Gynecologic Cancer.

[4]  B. Monk,et al.  Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study. , 2010, Gynecologic oncology.

[5]  Sun Young Lee,et al.  Photodynamic therapy for management of cervical intraepithelial neoplasia II and III in young patients and obstetric outcomes , 2013, Lasers in surgery and medicine.

[6]  B. Monk,et al.  Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Robert S Mannel,et al.  Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  C. Verschraegen,et al.  Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Mannel,et al.  A Phase II Trial of Erlotinib in Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study , 2009, International Journal of Gynecologic Cancer.

[10]  B. Monk,et al.  Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  P. Rose,et al.  Evaluation of pegylated liposomal doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. , 2006, Gynecologic oncology.

[12]  S. Pecorelli.  Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium , 2009 .

[13]  D. Alberts,et al.  Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M Arbyn,et al.  Worldwide burden of cervical cancer in 2008. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  F. Landoni,et al.  Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer , 1997, The Lancet.

[16]  C. Haie-meder,et al.  Prospective multicenter study evaluating the survival of patients with locally advanced cervical cancer undergoing laparoscopic para-aortic lymphadenectomy before chemoradiotherapy in the era of positron emission tomography imaging. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  F. Landoni,et al.  Chemo-conization in early cervical cancer. , 2007, Gynecologic oncology.

[18]  C. Köhler,et al.  Radical Vaginal Trachelectomy (RVT) Combined With Laparoscopic Lymphadenectomy: Prospective Study of 225 Patients With Early-Stage Cervical Cancer , 2011, International Journal of Gynecologic Cancer.

[19]  S. Pignata,et al.  Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  J. Tierney,et al.  Neoadjuvant chemotherapy for locally advanced cervix cancer , 2004 .

[21]  P Grigsby,et al.  Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Tierney,et al.  Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. , 2012, The Cochrane database of systematic reviews.

[23]  M. Peluffo,et al.  A possible new trend in the management of the carcinoma of the cervix uteri. , 1986, Gynecologic oncology.

[24]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.

[25]  B N Bundy,et al.  Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. , 1999, The New England journal of medicine.

[26]  F. Muggia.  Relevance of chemotherapy dose and schedule to outcomes in ovarian cancer. , 2004, Seminars in oncology.

[27]  D. Cella,et al.  Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  G. Scambia,et al.  Long-term survival following neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer. , 1998, European journal of cancer.

[29]  F. Landoni,et al.  Simple conization and lymphadenectomy for the conservative treatment of stage IB1 cervical cancer. An Italian experience. , 2011, Gynecologic oncology.

[30]  L Souhami,et al.  Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  P J Eifel,et al.  Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. , 1999, The New England journal of medicine.

[32]  K. Reynolds,et al.  Pre-treatment surgical para-aortic lymph node assessment in locally advanced cervical cancer. , 2013, The Cochrane database of systematic reviews.

[33]  D. Miller,et al.  Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  M. Friedlander,et al.  Guidelines for the treatment of recurrent and metastatic cervical cancer. , 2002, The oncologist.

[35]  F. X. Bosch,et al.  Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions , 2007 .

[36]  C. Dykewicz.  Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  J. Byun,et al.  Overall 5-year survival rate and prognostic factors in patients with stage IB and IIA cervical cancer treated by radical hysterectomy and pelvic lymph node dissection. , 2000, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[38]  T. Herzog,et al.  Topotecan in squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group. , 2000, Gynecologic oncology.

[39]  P. Grigsby,et al.  Tumor size, irradiation dose, and long-term outcome of carcinoma of uterine cervix. , 1998, International journal of radiation oncology, biology, physics.

[40]  T. Herzog,et al.  A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. , 2007, Gynecologic oncology.

[41]  M. Nair,et al.  Laparoscopic, robotic and open method of radical hysterectomy for cervical cancer: A systematic review , 2012, Journal of Minimal Access Surgery.

[42]  J. Reiber,et al.  Tumor diameter and volume assessed by magnetic resonance imaging in the prediction of outcome for invasive cervical cancer. , 2001, Gynecologic oncology.

[43]  Wei Hu,et al.  Chemotherapy for recurrent and metastatic cervical cancer. , 2008, Gynecologic oncology.

[44]  A. Dueñas-González,et al.  Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  M. Kane.  Preventing Cancer with Vaccines: Progress in the Global Control of Cancer , 2012, Cancer Prevention Research.

[46]  Ranjit Thorat,et al.  HPV screening for cervical cancer in rural India. , 2009, The New England journal of medicine.

[47]  N. Malamos,et al.  Evaluation of the paclitaxel–ifosfamide–cisplatin (TIP) combination in relapsed and/or metastatic cervical cancer , 2009, British Journal of Cancer.

[48]  P. Disaia,et al.  Survival and patterns of recurrence in cervical cancer metastatic to periaortic lymph nodes (a Gynecologic Oncology Group study). , 1984, Gynecologic oncology.

[49]  G. Scambia,et al.  Excisional cone as fertility-sparing treatment in early-stage cervical cancer. , 2011, Fertility and sterility.

[50]  B. Monk,et al.  Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  A. Schneider,et al.  Clinical Recommendation Radical Trachelectomy for Fertility Preservation in Patients With Early-Stage Cervical Cancer , 2011, International Journal of Gynecologic Cancer.

[52]  B N Bundy,et al.  Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. , 1999, The New England journal of medicine.

[53]  I. Barillot,et al.  Carcinoma of the intact uterine cervix treated with radiotherapy alone: a French cooperative study: update and multivariate analysis of prognostics factors. , 1997, International journal of radiation oncology, biology, physics.

[54]  R. Guy,et al.  Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data , 2013, BMJ : British Medical Journal.

[55]  B Romanowski,et al.  Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women , 2009, The Lancet.

[56]  D. Paladini,et al.  Radical surgery after induction chemotherapy in locally advanced cervical cancer. A feasibility study , 1994, International Journal of Gynecologic Cancer.

[57]  Clare Gilham,et al.  Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials , 2014, The Lancet.

[58]  A. Tinker,et al.  A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184. , 2010, Gynecologic oncology.

[59]  F. Gleeson,et al.  18F-FDG PET/CT of cervical carcinoma. , 2011, AJR. American journal of roentgenology.

[60]  Parker,et al.  Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials. , 2003, European journal of cancer.

[61]  R. Schilder,et al.  Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. , 2005, Gynecologic oncology.

[62]  B N Bundy,et al.  Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  R. Zaino,et al.  A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study. , 2006, International journal of radiation oncology, biology, physics.

[64]  D. Alberts,et al.  Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study. , 2012, Gynecologic oncology.

[65]  K. Kamposioras,et al.  Chemotherapy for recurrent cervical cancer. , 2008, Cancer treatment reviews.